CJC-1295 with Ipamorelin Telehealth
Physician-guided evaluation for growth hormone–signaling peptide therapy when clinically appropriate.
$99 Consultation | $300 Total If Approved
Understanding CJC-1295 with Ipamorelin
CJC-1295 and Ipamorelin are peptides studied for their roles in growth hormone–releasing pathways.
CJC-1295 acts as a growth hormone–releasing hormone (GHRH) analog, while Ipamorelin is a growth hormone secretagogue receptor agonist studied for its selective signaling properties.
Through telehealth, licensed medical providers determine whether therapy may be appropriate based on medical history and clinical evaluation.
Compounded peptide medications are not FDA-approved for the diagnosis, treatment, cure, or prevention of disease.
Who Typically Explores CJC-1295 with Ipamorelin?
- Maintain active training routines
- Focus on structured recovery
- Seek physician-guided oversight
- Prefer regulated pharmacy fulfillment
- Want clinical evaluation rather than self-directed sourcing
Appropriateness is determined only after consultation.q
How It Works
You’ll begin with a brief virtual consultation with a licensed medical provider, who will review your medical history and determine whether this therapy may be appropriate for you.
If treatment is recommended, your prescription is sent to a licensed U.S. compounding pharmacy and shipped directly to your home, typically within 3–7 business days.
Consultation Cost
The total cost is $300, which includes:
If a peptide therapy is not clinically appropriate, there is no charge for the visit.
- All therapies are prescribed only when clinically appropriate and based on physician evaluation.
A Structured Evaluation Process
Your first month of peptide therapy is bundled at $300 total (consultation included).
Additional peptides may be considered after the first month when clinically indicated. Additional therapies are typically $250 each.
No automatic subscriptions. No stacking without review.
Medical & Regulatory Considerations
CJC-1295 and Ipamorelin therapies may involve compounded formulations.
Compounded medications are not FDA-approved and may have limited long-term safety data.
These peptides may be considered investigational in certain contexts.
All prescribing decisions are based on physician evaluation and clinical appropriateness.
Statements on this website have not been evaluated by the FDA.
Individual results vary.
Frequently Asked Questions
These peptides are studied for their influence on endogenous growth hormone signaling pathways. Clinical effects vary and depend on individual physiology.
No. CJC-1295 and Ipamorelin differ from recombinant human growth hormone and operate through different biological signaling pathways.
Compounded peptide therapy is legal when prescribed by a licensed medical provider and fulfilled by a licensed pharmacy in compliance with state and federal regulations.
No. All prescribing decisions require physician evaluation and approval.
Interested in CJC-1295 with Ipamorelin?
Schedule your $99 physician consultation to determine clinical appropriateness.